In this study, we aimed to investigate whether PET, CSF and plasma biomarkers of tau pathology in AD are comparable to each other or carry unique information about AD‐related demographic, cognitive, genetic and neuroimaging markers. This evidence concerns the gene MAPT and Alzheimer disease.